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SUMMARY  Thalidomide is a beneficial agent for treating a variety 
of refractory dermatologic disorders including erythema nodosom 
leprosum, lupus erythematosus, prurigo nodularis, actinic prurigo, 
pyoderma gangrenosum and aphthous stomatitis. Two thalidomide 
analogues, lenalidomide and CC-4047, are considerably more potent 
with decreased side effects when compared to thalidomide. They are 
currently undergoing trials and show promise, as they have increased 
immunomodulatory and anti-angiogenic activity. This category of 
medication and its use will be reviewed.
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BACKGROUND 
 Thalidomide, first introduced as a sedative but 
quickly withdrawn from the market as a cause of 
severe birth defects, is making a comeback (1). 
It now has U.S. Food and Drug Administration 
(FDA) approved use in the treatment of erythema 
nodosum leprosum. It may be useful in unrespon-
sive dermatologic conditions including actinic pru-
rigo, adult Langerhans cell histiocytosis, aphthous 
stomatitis, Behçet’s syndrome, graft-versus-host 
disease, cutaneous sarcoidosis, erythema mul-
tiforme, Jessner-Kanof lymphocytic infiltration of 
the skin, Kaposi sarcoma, lichen planus, lupus 
erythematosus, prurigo nodularis, pyoderma gan-
grenosum and uremic pruritus (1). This article 
reviews the history, pharmacology, mechanism 
of action, clinical uses and adverse effects of 
thalidomide. 
 Thalidomide was first synthesized in Germany 
in 1954 as α-N-phthalimidoglutarimide (1,2) (Fig. 
1). In 1957, it was first approved in Germany as 
a sedative and hynoptic under the trade name 
Contergan®.  Other countries including the United 
Kingdom, Canada and Australia marketed this 
drug under various trade names. Additional uses 
at that time was for the treatment of irritability, 
stage fright, depression and hypothyroidism (3). 
Subsequently, thalidomide was used as an anti-
emetic because of its efficacy in treating morning 
sickness in pregnant women (4). In spite of its clin-
ical efficacy, it is the safety profile that is the most 
disturbing aspect of this drug.
 In 1961, thalidomide was implicated in causing 
a severe fetal defect known as phocomelia. The 
neonates had congenital foreshortening of the 
limbs that was usually bilateral and non-symmet-
ric. Approximately 6,000-10,000 live births were 
affected by this drug; this incurred medico-legal 
costs totaling more that 27 million dollars (2,5). 
Due to the concerns about the side effects, the 
approval of thalidomide was delayed by the U.S. 
FDA (3). However, its uses continued to be ex-
plored on an experimental basis (2).
 Then in 1965, thalidomide was used as a seda-
tive to relieve the suffering of leprosy patients. In 
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addition to its sedative effect, there were marked 
clinical improvement in the signs and symptoms 
of erythema nodosum leprosum (ENL). These re-
sults were duplicated in other countries and even-
tually in 1998, thalidomide was granted an “or-
phan drug” status in the treatment of ENL by the 
U.S. FDA. However, the dispensing of thalidomide 
is highly restricted through the System for Thalido-
mide Education and Prescribing Safety (STEPS) 
program, implemented to reduce the potential for 
fetal toxicity (4). 
 Thalidomide has also shown potential in the 
treatment of multiple myeloma, myelodysplasia, 
leukemia, mantle cell lymphoma, glioblastoma 
multiforme, metastatic melanoma, pancreatic can-
cer, prostatic cancer, colorectal cancer, renal cell 
carcinoma, cancer cachexia, HIV or tuberculosis 
associated wasting, neuropathic pain and intrac-
table insomnia (4,5). This review will focus on the 
off-label uses of thalidomide in the treatment of re-
fractory dermatologic diseases (Table 1). The dos-
age for dermatologic conditions ranges from 100 
to 400 mg/day orally while other conditions, mainly 
oncologic, may require higher doses at 200-800 
mg/day (4).
PHARMACOLOGY OF THALIDOMIDE
 The exact mechanism of action of thalidomide 
is still unclear. However, thalidomide has been 
shown to have sedative, anti-inflammatory, immu-
nomodulatory and anti-angiogenesis activity (Ta-
ble 2). Thalidomide has also been found to inhibit 
tumor necrosis factor-α (TNF-α) synthesis, possi-
bly by increasing the degradation of TNF-α mRNA 
(4). This cytokine, produced by various proinflam-
matory cells, has been implicated in various infec-
tions and autoimmune disorders such as ENL (4). 
Thalidomide is well absorbed orally reaching max-
imal plasma levels of 1-4 μg/mL within 2-4 hours. 
It has a half-life of 10 hours and a clearance of 10 
L/h (3). Thalidomide is metabolized into inactive 
chemical metabolites via pH dependent spontane-
ous hydrolysis (5). The excretion route of thalido-
mide is still unclear; furthermore, enhanced effects 
of alcohol and barbiturates were demonstrated 
when taken concomitantly with thalidomide. Tha-
lidomide also raises the levels of acetaminophen; 
it, however, was not shown to alter the pharmaco-
kinetics of oral contraceptive pills (1,3).  
ADVERSE EFFECTS
 Thalidomide is teratogenic and therefore con-
traindicated for use in pregnant patients. It is 
designated as pregnancy category X. Peripheral 
neuropathy is also a side effect that greatly affects 
compliance. It has been found to occur with the 
greatest risk in the first year of treatment (1). Other 
common side effects include sedation, constipa-
tion, pruritus, weight gain and dizziness. It is im-
portant to note that dermatologic side effects can 
also occur, including but not limited to exfoliative 
Figure 1. The structure of thalidomide.
Table 1. Dermatologic uses of thalidomide (3,11)
Actinic prurigo                               Kaposi sarcoma       
Prurigo nodularis                           Lupus erythematous profundus
Behçet disease                              Chronic discoid lupus erythematosus
Polymorphous light eruption          Leishmaniasis cutanea recidivans
Pemphigoid disorders                   Cold hemagglutinin disease 
Plantar vasculitis                           Jessner-Kanof disease
Immune complex vasculitis           Lichen planus
Histiocytosis                                  Erosive lichen planus
Langerhans cell histiocytosis        Porphyria cutanea tarda
Postherpetic neuralgia                  Photodermatosis
Uremic pruritis                               Rheumatoid arthritis
Pyoderma gangrenosum               Cutaneous sarcoidosis
Erythema multiforme                     Cutaneous lymphoid hyperplasia
Esophageal ulceration in AIDS      Perineal ulceration in AIDS
Recurrent aphthous stomatitis       Laryngo-onychocutaneous syndrome (26)
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dermatitis, toxic epidermal necrolysis (TEN), ex-
acerbation of psoriasis, and allergic vasculitis (1).
 Thalidomide showed an increased risk of ve-
nous thrombosis in patients that had thrombotic 
risk associated diseases including cancer and 
lupus with antiphospholipid antibody syndrome 
(6). Therefore, thalidomide should be used with 
caution in these individuals. In addition, thalido-
mide at one time was thought to be effective as a 
therapy for TEN; however, it is not recommended 
in the treatment of this condition because of the 
increased mortality that was demonstrated (1,7). 
IMiD ANALOGUES
 Lenalidomide (Revlimid®) and CC-4047 (Actim-
id®) are analogues of thalidomide that are 2,000 
and 20,000 times more potent, respectively (4). 
These analogues, referred to as iMiDs, are cur-
rently undergoing trials for various indications in-
cluding multiple myeloma, amyloidosis and pros-
tate cancer (4,8). They show promise as they have 
increased immunomodulatory and anti-angiogenic 
activity and decreased side effects when compared 
to thalidomide (4). These analogues were found to 
costimulate T cells, possibly allowing these drugs 
to act as adjuvants to promote T cell responses 
for antitumor activity (8). In addition, lenalidomide 
was shown to be non-teratogenic in animal stud-
ies, which adds to its favorable side effect profile 
(4). However, the cutaneous side effects that did 
occur were similar to thalidomide (9). 
 One study showed that at least one third of pa-
tients on lenalidomide therapy developed rashes 
(9). The prevalence of rashes in those taking le-
nalidomide was similar to those taking lenalido-
mide with systemic steroids. There appeared to be 
less dermatologic side effects in this study when 
compared to thalidomide studies. In addition, 
there was one patient with neutrophilic dermatosis 
attributed to treatment with lenalidomide (10).
THALIDOMIDE AND DERMATOLOGIC 
CONDITIONS
 Erythema nodosum leprosum 
 Thalidomide has shown efficacy in the treat-
ment of ENL; however, the mechanism by which 
it helps is unknown. There are increased levels of 
TNF-αand interferon-γ (INF-γ) in ENL; thalidomide 
has been shown to exert an immunomodulatory 
effect by decreasing these levels. Currently, tha-
lidomide’s only approved indication is in the treat-
ment of ENL. Clinically, a decrease in skin lesions 
was observed in the first 2 days with complete re-
mission within 2 weeks at response rates greater 
than 90% (1,11). In addition, headaches, myalgia, 
emesis and iritis resolved as well with this treat-
ment.  The optimal initial dose is 300-400 mg/day 
with maintenance doses of 50-100 mg/day. Fifty 
percent of the patients usually require treatment 
for at least 6 years (3). 
 Lupus erythematosus 
 Thalidomide was demonstrated to be effective 
in the treatment of cutaneous lupus erythemato-
sus and discoid lupus erythematosus. Cutaneous 
lupus erythematosus (LE) patients refractory to 
other options showed marked clinical improvement 
with the use of low dose thalidomide (100 mg/day) 
(12). Of the 23 subjects in this study, 21 (91%) pa-
tients demonstrated a response in the first 8 weeks 
of treatment. However, it can recur soon after stop-
ping the treatment, but was once again responsive 
when restarted on thalidomide (1).
 Brocard et al. conducted a study in 18 pa-
tients who had chronic discoid LE. Fifteen pa-
tients showed complete or partial remission, two 
patients were stabilized, and one patient failed 
treatment. The mean initial dose ranged from 50 
to 100 mg/day, followed by a maintenance dose of 
50 mg/day (13). In another study of discoid LE pa-
tients on low dose thalidomide therapy, complete 
remission was observed in 54.5% of patients. The 
median remission rate was 1 month in 40% of pa-
tients (14). 
 Prurigo nodularis 
 Prurigo nodularis (PN) is an often troubling 
chronic disorder characterized by pruritic excori-
Table 2. Effects of thalidomide (1,5)
Sedative effects:
Activity at the sleep center in the forebrain
Immunomodulatory:
Inhibit tumor necrosis factor-α (TNF-α) synthesis
Inhibit interleukin (IL) 6, 8, 12 synthesis 
Inhibit NF-κβ gene expression
Enhance interferon-γ (IFN-γ) synthesis
Enhance IL-2, 4, 5, 10
Inhibit phagocytosis by neutrophils
Inhibit chemotaxis of monocytes and leukocytes
Switch cytokine production from Th1 to Th2 lineage
Anti-angiogenesis:
Inhibit synthesis of vascular endothelial derived growth 
factor 
Inhibit synthesis of basic fibroblast growth factor
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ated nodules of 0.5-3 cm in diameter. The usual 
treatment with antihistamines and steroids, either 
topical or systemic, is often ineffective (15). Tha-
lidomide has proven to be of value in the treat-
ment of PN in several studies, possibly attributed 
to its effect on the proliferated neural tissue (1). In 
a study of 22 patients, thalidomide 50-300 mg dai-
ly was given to patients for an average of 1 year. 
Twenty patients had a significant decrease in pru-
ritus, in addition to reporting a decrease in the size 
and number of skin lesions after 1-2 months. Sev-
enty percent of patients on thalidomide treatment 
also had peripheral neuropathy as a side effect; 
some of these patients had to discontinue treat-
ment (1).
 Actinic prurigo
 Actinic prurigo (AP) is a photodermatosis 
that is characterized by erythematous papules, 
crusts and lichenified plaques in association with 
chronic pruritus. This condition, prevalent in Latin 
America, usually develops on sun-exposed ar-
eas. Interestingly, cases that develop in the US, 
Canada and England have shown a pattern of ex-
acerbation in the spring and summer, while Latin 
American cases generally are chronic with no re-
missions. This condition is treated with antibiotics, 
antihistamines, and oral or systemic corticoste-
roids (16). 
 Several studies show that thalidomide is effec-
tive in the treatment of this condition. Thirty-four 
patients were given 300 mg of thalidomide daily, 
which was tapered to 15 mg daily. Of these pa-
tients, only two patients did not show clinical im-
provement in 50 days (1). Another study consisted 
of a patient that was refractory to other standard 
treatments. He showed clinical improvement in 
2 months at an initial dose of 100 mg daily, with 
a maintenance dose of 50 mg daily. It should be 
noted that the patient had multiple recurrences 
upon stopping the treatment and therefore had to 
continue the medication at 50 mg/day (17).
 Lichen planus
 Oral lichen planus is an idiopathic condition 
that affects 1%-2% of the population and has a 
low remission rate of 5% (18). Lichen planus has 
been treated using a variety of medications. One 
patient with oral lichen planus refractory to the 
usual agents showed 75% improvement in symp-
toms after 4 months of treatment with 50-200 mg/
day of thalidomide (18). In a retrospective study 
of six patients with erosive oral lichen planus, five 
patients showed a complete to partial response to 
thalidomide. These patients did, however, relapse 
once the drug therapy ended (1).
 Melanoma
Thalidomide has anti-angiogenic properties that 
lend to its ability to be beneficial in selected pa-
tients with metastatic melanoma (1). A study in-
cluding 20 patients presenting with malignant 
melanoma without symptomatic brain metastases 
showed stable disease in 7/20 patients (35%) for 
12-32 weeks with thalidomide dosed at 200-800 
mg/day (1). Alternatively, another study had 14 
patients with metastatic malignant melanoma as-
sessed for a response to thalidomide. In the light of 
unchanged serum levels of basic fibroblast growth 
factor (b-FGF) and vascular endothelial growth 
factor (VEGF), thalidomide was not recommended 
as a single agent in the treatment (19).
 Melanoma is the third most common tumor to 
metastasize to the brain. In a phase II trial assess-
ing the benefits of temozolomide and thalidomide, 
15/26 patients completed at least one trial. Three 
patients had a complete or partial response and 
7 had stable or minor responses (20). In a phase 
I study conducted by Bartlett et al., lenalidomide 
was studied in patients with metastatic malignant 
melanoma and other advanced cancers. Their 
results demonstrated that lenalidomide was safe 
and tolerable in these cancers (8). In addition, al-
though they were not testing efficacy, they have 
reported that their data suggest clinical activity in 
the treatment of these diseases (8). Further stud-
ies need to be conducted to assess the efficacy 
of the iMiD analogues in the treatment of these 
conditions. 
 Pyoderma gangrenosum
 Pyoderma gangrenosum, a chronic painful ul-
cerative disorder, may benefit from thalidomide 
treatment (11). A patient with a 27-year history of 
pyoderma gangrenosum refractory to standard 
treatments showed improvement with a 6-month 
course of thalidomide. The lesions healed with 
scarring; no new ones appeared during this time 
(21). Another patient, refractory to methylprednis-
olone treatment, showed complete healing in 10 
weeks with thalidomide therapy (1).
 Aphthous stomatitis
 Thalidomide was first reported to be beneficial 
in the treatment of recurrent aphthous stomatitis 
in 1979 (1). Six patients were treated with 100 mg/
day of thalidomide with complete resolution in 7-10 
days (1). In a multicenter, crossover, randomized 
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trial in patients with more that 6-month duration 
of severe aphthous stomatitis, thalidomide was 
compared to placebo. Complete remission was 
observed in 32 patients on thalidomide 100 mg/
day compared to six patients in the placebo group 
(22). In 17 patients that were refractory to standard 
treatments for recurrent aphthous stomatitis, 59% 
achieved complete or partial response on doses of 
thalidomide ranging from 50 to 150 mg daily (23).
  Other cutaneous disorders
 Thalidomide may be useful for a wide variety of 
other disorders. It may improve the mucocutane-
ous findings and hypothalamic derangements of 
adult multisystem Langerhans cell histiocytosis. 
With 200 mg/day of thalidomide, one patient had 
a rapid response to treatment with a decrease in 
skin manifestations and diabetes insipidus (24). 
Severe cicatrical pemphigoid that is refractory 
to other standard treatments was also shown to 
benefit from thalidomide treatment (25). A patient 
demonstrated improved mucosal and cutaneous 
lesions after treatment with thalidomide for 26 
months (25).
CONCLUSION
 Thalidomide has been shown to be effective in 
the treatment of various refractory dermatologic 
conditions including erythema nodusom leprosum, 
lupus erythematosus, prurigo nodularis, actinic 
prurigo, lichen planus, pyoderma gangrenosum 
and aphthous stomatitis. The length of therapy 
and dosing, which ranges from 100-800 mg/day, 
depends on the condition. Many reports have 
shown that, upon stopping thalidomide therapy, 
recurrences of the condition can occur.  
 The side effect profile, i.e. teratogenicity and 
peripheral neuropathy, is an important factor to 
consider when recommending thalidomide as 
a treatment option. STEPS, a program created 
to restrict inappropriate thalidomide usage, has 
been implemented so that various patient factors 
are assessed prior to dispensing the prescription. 
Other iMiD analogues such as lenalidomide and 
CC-4047 show improved activity and side effect 
profiles compared to thalidomide. Further studies 
are necessary to prove the efficacy and safety of 
thalidomide and its analogues in the treatment of 
dermatologic conditions.
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